U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H21N5O2S2
Molecular Weight 331.4601
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NIZATIDINE

SMILES

CNC(=CN(=O)=O)NCCSCc1csc(CN(C)C)n1

InChI

InChIKey=SGXXNSQHWDMGGP-WDZFZDKYSA-N
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6-

HIDE SMILES / InChI

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/2892249

Nizatidine reduced gastric acid secretion for up to 8 h suggesting that this compound could be used in with a once or twice daily dosage regime. Nizatidine was rapidly and well-absorbed orally, was widely distributed in tissues and the majority of the dose was excreted in the urine within 24 h. Nizatidine is indicated for duodenal and gastric ulcer as well as for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gastroesophageal reflux disease.

CNS Activity

Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/8619239

Originator

Sources: R.P. Pioch (Lilly, Eli and Co.) U.S. 4.382.090, 03 May 1983, U.S. Appl. 193.192, 02 Oct. 1980, 23 pp. Cont.- in part of U.S. 4.375.547; Chem. Abstr. 99 43548w (1983).
Curator's Comment:: Reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9260662

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NIZATIDINE

Approved Use

Nizatidine capsules USP are indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine capsules USP are indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine capsules USP are indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine capsules USP are indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

Launch Date

1310601600000
Primary
NIZATIDINE

Approved Use

Nizatidine capsules USP are indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine capsules USP are indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine capsules USP are indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine capsules USP are indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

Launch Date

1310601600000
Primary
NIZATIDINE

Approved Use

Nizatidine capsules USP are indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine capsules USP are indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine capsules USP are indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine capsules USP are indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

Launch Date

1310601600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1422.9 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIZATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
1480.2 ng/mL
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NIZATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
1367.6 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIZATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3764.2 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIZATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
3776.1 ng × h/mL
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NIZATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
3703.1 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIZATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.2 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIZATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
1.3 h
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NIZATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
1.4 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIZATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
65%
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIZATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Disc. AE: Peptic ulcer disease, Cough...
AEs leading to
discontinuation/dose reduction:
Peptic ulcer disease
Cough
Sources:
AEs

AEs

AESignificanceDosePopulation
Cough Disc. AE
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Peptic ulcer disease Disc. AE
300 mg 1 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Influence of H2-receptor- and proton pump inhibitors on some functions of the oxydative and conjugative drug metabolism.
1996 Jul
Nizatidine-induced delirium in a nonagenarian.
1997 Jul
Effects of different antisecretory drugs on gastric potential difference in the rat: comparison with sucralfate.
1998 Dec
Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide.
2002 Nov
Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis.
2005 Feb
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Patents

Sample Use Guides

Active Duodenal Ulcer: The recommended oral dosage of adults is 300 mg once daily at bedtime. An alternative dosage regimen is 150 mg twice daily.
Route of Administration: Oral
In Vitro Use Guide
In guinea pig antral muscle strips nizatidine increased the amplitude of spontaneous phasic antral contractions in a concentration-dependent fashion with threshold concentrations of 5 uM. In isolated cells, nizatidine induced concentration-dependent cell shortening, with maximal shortening at 10 uM.
Name Type Language
NIZATIDINE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
NIZATIDINE [USP]
Common Name English
NIZATIDINE [HSDB]
Common Name English
NIZATIDINE [USP-RS]
Common Name English
NSC-759289
Code English
ACINON
Brand Name English
1,1-ETHENEDIAMINE, N-(2-(((2-((DIMETHYLAMINO)METHYL)-4-THIAZOLYL)METHYL)THIO)ETHYL)-N'-METHYL-2-NITRO-
Systematic Name English
NIZATIDINE [EP MONOGRAPH]
Common Name English
NIZATIDINE [INN]
Common Name English
NIZATIDINE [JAN]
Common Name English
LY 139037
Code English
NIZATIDINE [WHO-DD]
Common Name English
NIZATIDINE [VANDF]
Common Name English
NIZATIDINE [USP MONOGRAPH]
Common Name English
NIZATIDINE [ORANGE BOOK]
Common Name English
AXID
Brand Name English
N-(2-(((2-((DIMETHYLAMINO)METHYL)-4-THIAZOLYL)METHYL)THIO)ETHYL)-N'-METHYL-2-NITRO-1,1-ETHENE DIAMINE
Common Name English
AXID AR
Brand Name English
NIZATIDINE [MART.]
Common Name English
NIZATIDINE [MI]
Common Name English
NIZATIDINE [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX 693
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
NDF-RT N0000175784
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
WHO-VATC QA02BA04
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
NDF-RT N0000000151
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
NCI_THESAURUS C29702
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
WHO-ATC A02BA04
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
Code System Code Type Description
USP_CATALOG
1467804
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY USP-RS
HSDB
3574
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
LACTMED
Nizatidine
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
MERCK INDEX
M8017
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY Merck Index
PUBCHEM
4513
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
MESH
D016567
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
CAS
76963-41-2
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
DRUG CENTRAL
1955
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
IUPHAR
7248
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
EPA CompTox
76963-41-2
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
EVMPD
SUB09335MIG
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
DRUG BANK
DB00585
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
NCI_THESAURUS
C29295
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
RXCUI
42319
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
NIZATIDINE
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
ChEMBL
CHEMBL653
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
INN
5194
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY
FDA UNII
P41PML4GHR
Created by admin on Fri Jun 25 21:00:57 UTC 2021 , Edited by admin on Fri Jun 25 21:00:57 UTC 2021
PRIMARY